Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$1.74
-4.4%
$2.19
$1.29
$48.72
$9.55M0.641.16 million shs90,140 shs
Exscientia plc stock logo
EXAI
Exscientia
$4.84
$4.97
$3.80
$6.49
$632.93M0.83624,981 shsN/A
Intel Co. stock logo
INTC
Intel
$18.93
-1.6%
$22.38
$17.67
$37.16
$82.55B1.1378.47 million shs85.40 million shs
NVIDIA Co. stock logo
NVDA
NVIDIA
$101.33
-3.0%
$117.19
$75.61
$195.95
$2.47T1.96312.56 million shs290.59 million shs
Renovaro Inc. stock logo
RENB
Renovaro
$0.35
-2.1%
$0.68
$0.32
$2.38
$55.96M0.59927,040 shs390,482 shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$2.69
+3.1%
$3.13
$1.78
$10.72
$456.01M1.71.97 million shs1.63 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$5.50
+3.4%
$6.66
$3.79
$12.36
$2.21B112.00 million shs12.71 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
0.00%+1.68%-20.18%-67.11%-95.76%
Exscientia plc stock logo
EXAI
Exscientia
0.00%0.00%0.00%0.00%+13.88%
Intel Co. stock logo
INTC
Intel
-3.12%-10.68%-25.15%-2.31%-46.97%
NVIDIA Co. stock logo
NVDA
NVIDIA
-6.87%-8.61%-12.58%-21.77%+19.53%
Renovaro Inc. stock logo
RENB
Renovaro
-3.64%-13.21%-53.12%-52.00%-85.12%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-5.43%+13.48%-25.64%-39.37%-61.28%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-5.67%+14.41%-22.22%-16.88%-29.72%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
4.002 of 5 stars
3.33.00.04.52.71.70.6
Exscientia plc stock logo
EXAI
Exscientia
0.561 of 5 stars
2.00.00.00.00.01.70.6
Intel Co. stock logo
INTC
Intel
4.4119 of 5 stars
4.05.00.02.42.61.71.3
NVIDIA Co. stock logo
NVDA
NVIDIA
4.8864 of 5 stars
4.55.01.73.02.62.51.9
Renovaro Inc. stock logo
RENB
Renovaro
0.5545 of 5 stars
0.01.00.00.01.33.30.6
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.3892 of 5 stars
3.43.00.00.01.62.50.6
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.1343 of 5 stars
3.22.00.00.02.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
2.67
Moderate Buy$42.602,348.28% Upside
Exscientia plc stock logo
EXAI
Exscientia
2.00
Hold$6.0023.97% Upside
Intel Co. stock logo
INTC
Intel
1.94
Reduce$25.3834.05% Upside
NVIDIA Co. stock logo
NVDA
NVIDIA
2.93
Moderate Buy$165.5163.35% Upside
Renovaro Inc. stock logo
RENB
Renovaro
0.00
N/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.82
Moderate Buy$18.36582.66% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.33
Hold$8.2049.09% Upside

Current Analyst Ratings Breakdown

Latest INTC, NVDA, RXRX, RLAY, EXAI, RENB, and BTAI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2025
NVIDIA Co. stock logo
NVDA
NVIDIA
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$185.00 ➝ $180.00
4/17/2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$4.00
4/16/2025
NVIDIA Co. stock logo
NVDA
NVIDIA
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy
4/16/2025
NVIDIA Co. stock logo
NVDA
NVIDIA
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/16/2025
Intel Co. stock logo
INTC
Intel
Susquehanna
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$24.00 ➝ $22.00
4/16/2025
NVIDIA Co. stock logo
NVDA
NVIDIA
Rosenblatt Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$220.00 ➝ $200.00
4/16/2025
NVIDIA Co. stock logo
NVDA
NVIDIA
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
4/16/2025
NVIDIA Co. stock logo
NVDA
NVIDIA
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$175.00 ➝ $150.00
4/16/2025
NVIDIA Co. stock logo
NVDA
NVIDIA
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
4/16/2025
NVIDIA Co. stock logo
NVDA
NVIDIA
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetStrong-Buy ➝ Strong-Buy$170.00 ➝ $150.00
4/16/2025
NVIDIA Co. stock logo
NVDA
NVIDIA
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$200.00 ➝ $160.00
(Data available from 4/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$2.27M4.21N/AN/A($30.21) per share-0.06
Exscientia plc stock logo
EXAI
Exscientia
$25.60M24.72N/AN/A$2.54 per share1.91
Intel Co. stock logo
INTC
Intel
$53.10B1.55$1.29 per share14.65$24.26 per share0.78
NVIDIA Co. stock logo
NVDA
NVIDIA
$130.50B18.95$0.90 per share112.93$1.72 per share58.91
Renovaro Inc. stock logo
RENB
Renovaro
N/AN/AN/AN/A$0.52 per shareN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$10.01M45.57N/AN/A$5.90 per share0.46
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$58.49M37.80N/AN/A$1.98 per share2.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$179.05M-$25.97N/AN/AN/A-3,119.33%N/A-105.04%5/8/2025 (Estimated)
Exscientia plc stock logo
EXAI
Exscientia
-$181.56M-$1.51N/AN/AN/A-882.09%-49.10%-33.13%N/A
Intel Co. stock logo
INTC
Intel
-$18.76B-$4.38N/A33.80N/A-35.32%-3.27%-1.83%4/24/2025 (Estimated)
NVIDIA Co. stock logo
NVDA
NVIDIA
$29.76B$2.9439.8825.461.7655.69%114.83%76.61%5/28/2025 (Estimated)
Renovaro Inc. stock logo
RENB
Renovaro
-$80.65M-$0.93N/AN/AN/A-61.84%-48.07%5/13/2025 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$341.97M-$2.39N/AN/AN/AN/A-45.75%-40.75%5/1/2025 (Estimated)
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$328.07M-$1.66N/AN/AN/A-579.52%-76.56%-55.68%5/8/2025 (Estimated)

Latest INTC, NVDA, RXRX, RLAY, EXAI, RENB, and BTAI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025N/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$2.72N/AN/AN/A$0.35 millionN/A
5/8/2025Q1 2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.44N/AN/AN/A$18.12 millionN/A
5/1/2025Q1 2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.51N/AN/AN/A$0.01 millionN/A
4/24/2025Q1 2025
Intel Co. stock logo
INTC
Intel
$0.0017N/AN/AN/A$12.26 billionN/A
3/27/2025Q4 2024
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$4.36-$3.57+$0.79-$3.57$0.72 million$0.30 million
2/28/2025Q4 2024
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.36-$0.53-$0.17-$0.53$19.04 million$4.60 million
2/26/2025Q4 2025
NVIDIA Co. stock logo
NVDA
NVIDIA
$0.84$0.89+$0.05$0.89$38.16 billion$39.33 billion
2/26/2025Q4 2024
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.57-$0.45+$0.12-$0.45$5.53 millionN/A
2/19/2025Q2 2025
Renovaro Inc. stock logo
RENB
Renovaro
N/A-$0.02N/A-$0.04N/AN/A
1/30/2025Q4 2024
Intel Co. stock logo
INTC
Intel
$0.12-$0.02-$0.14-$0.03$13.83 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/AN/AN/AN/AN/A
Exscientia plc stock logo
EXAI
Exscientia
N/AN/AN/AN/AN/A
Intel Co. stock logo
INTC
Intel
$0.502.64%-28.88%N/A N/A
NVIDIA Co. stock logo
NVDA
NVIDIA
$0.040.04%+33.42%1.36%N/A
Renovaro Inc. stock logo
RENB
Renovaro
N/AN/AN/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A

Latest INTC, NVDA, RXRX, RLAY, EXAI, RENB, and BTAI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/26/2025
NVIDIA Co. stock logo
NVDA
NVIDIA
quarterly$0.010.03%3/12/20253/12/20254/2/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/A
1.87
1.81
Exscientia plc stock logo
EXAI
Exscientia
0.06
4.54
4.54
Intel Co. stock logo
INTC
Intel
0.44
1.33
0.98
NVIDIA Co. stock logo
NVDA
NVIDIA
0.13
4.10
3.64
Renovaro Inc. stock logo
RENB
Renovaro
N/A
0.06
0.08
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
18.42
18.42
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.04
4.35
4.35

Institutional Ownership

CompanyInstitutional Ownership
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
30.68%
Exscientia plc stock logo
EXAI
Exscientia
41.58%
Intel Co. stock logo
INTC
Intel
64.53%
NVIDIA Co. stock logo
NVDA
NVIDIA
65.27%
Renovaro Inc. stock logo
RENB
Renovaro
71.41%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%

Insider Ownership

CompanyInsider Ownership
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
21.20%
Exscientia plc stock logo
EXAI
Exscientia
16.40%
Intel Co. stock logo
INTC
Intel
0.04%
NVIDIA Co. stock logo
NVDA
NVIDIA
4.23%
Renovaro Inc. stock logo
RENB
Renovaro
21.72%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
4.32%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
15.75%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
905.49 million2.44 millionOptionable
Exscientia plc stock logo
EXAI
Exscientia
280130.77 million109.32 millionOptionable
Intel Co. stock logo
INTC
Intel
131,9004.36 billion4.33 billionOptionable
NVIDIA Co. stock logo
NVDA
NVIDIA
26,20024.40 billion23.45 billionOptionable
Renovaro Inc. stock logo
RENB
Renovaro
20158.72 million124.24 millionOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
330169.52 million160.15 millionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400401.99 million329.18 millionOptionable

Recent News About These Companies

Recursion and HealthVerity announce agreement

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioXcel Therapeutics stock logo

BioXcel Therapeutics NASDAQ:BTAI

$1.74 -0.08 (-4.40%)
Closing price 04:00 PM Eastern
Extended Trading
$1.78 +0.04 (+2.53%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Exscientia stock logo

Exscientia NASDAQ:EXAI

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Intel stock logo

Intel NASDAQ:INTC

$18.93 -0.30 (-1.56%)
Closing price 04:00 PM Eastern
Extended Trading
$18.94 +0.02 (+0.08%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intel Corporation designs, develops, manufactures, markets, and sells computing and related products and services worldwide. It operates through Client Computing Group, Data Center and AI, Network and Edge, Mobileye, and Intel Foundry Services segments. The company's products portfolio comprises central processing units and chipsets, system-on-chips (SoCs), and multichip packages; mobile and desktop processors; hardware products comprising graphics processing units (GPUs), domain-specific accelerators, and field programmable gate arrays (FPGAs); and memory and storage, connectivity and networking, and other semiconductor products. It also offers silicon devices and software products; and optimization solutions for workloads, such as AI, cryptography, security, storage, networking, and leverages various features supporting diverse compute environments. In addition, the company develops and deploys advanced driver assistance systems (ADAS), and autonomous driving technologies and solutions; and provides advanced process technologies backed by an ecosystem of IP, EDA, and design services, as well as systems of chips, including advanced packaging technologies, software and accelerate bring-up, and integration of chips and driving standards. Further, it delivers and deploys intelligent edge platforms that allow developers to achieve agility and drive automation using AI for efficient operations with data integrity, as well as provides hardware and software platforms, tools, and ecosystem partnerships for digital transformation from the cloud to edge. The company serves original equipment manufacturers, original design manufacturers, cloud service providers, and other manufacturers and service providers. It has a strategic agreement with Synopsys, Inc. to develop EDA and IP solutions; and ARM that enables chip designers to build optimized compute SoCs on the Intel 18A process. Intel Corporation was incorporated in 1968 and is headquartered in Santa Clara, California.

NVIDIA stock logo

NVIDIA NASDAQ:NVDA

$101.33 -3.16 (-3.03%)
Closing price 03:59 PM Eastern
Extended Trading
$101.14 -0.18 (-0.18%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.

Renovaro stock logo

Renovaro NASDAQ:RENB

$0.35 -0.01 (-2.06%)
Closing price 04:00 PM Eastern
Extended Trading
$0.35 +0.00 (+0.11%)
As of 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$2.69 +0.08 (+3.07%)
Closing price 04:00 PM Eastern
Extended Trading
$2.68 -0.02 (-0.56%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$5.50 +0.18 (+3.38%)
Closing price 04:00 PM Eastern
Extended Trading
$5.52 +0.01 (+0.27%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.